Is Mondelez Stock Overvalued?
The company behind Oreo, Ritz, LU, Clif Bar, and Tate’s…
Sell
11
NGNE Quote, Financials, Valuation and Earnings
Last price:
$15.62
Seasonality move
:
0.64%
Day range:
$15.92 - $16.85
52-week range:
$14.44 - $74.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.73x
Volume:
199.6K
Avg. volume:
233.6K
1-year change:
-47.01%
Market cap:
$237.2M
Revenue:
--
EPS (TTM):
-$3.09
Analysts' Opinion
-
Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $52.80, Neurogene has an estimated upside of 217.69% from its current price of $15.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $45.00 representing 100% downside risk from its current price of $15.95.
Fair Value
-
According to the consensus of 5 analysts, Neurogene has 217.69% upside to fair value with a price target of $52.80 per share.
NGNE vs. S&P 500
-
Over the past 5 trading days, Neurogene has underperformed the S&P 500 by -12.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Neurogene does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Neurogene has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Neurogene reported revenues of $925K.
Earnings Growth
-
Neurogene has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Neurogene reported earnings per share of -$1.19.
Enterprise value:
107.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.52x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-2176.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$56.3M | -$75.8M | -$15.2M | -$22.2M | |
| EBITDA | -- | -$51.5M | -$50M | -$13.7M | -$19.4M | |
| Diluted EPS | -- | -$27.81 | -$3.09 | -$1.14 | -$1.19 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $49.1M | $143.6M | |
| Total Assets | -- | -- | -- | $74M | $164.1M | |
| Current Liabilities | -- | -- | -- | $9.4M | $15.8M | |
| Total Liabilities | -- | -- | -- | $257.2M | $26.7M | |
| Total Equity | -- | -- | -- | -$183.2M | $137.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -$70.1M | -$11.6M | -$15.6M | |
| Cash From Investing | -- | -- | $3.2M | -$82K | -$29M | |
| Cash From Financing | -- | -- | $88.3M | -$1.8M | $131K | |
| Free Cash Flow | -- | -- | -$70.9M | -$11.7M | -$15.7M | |
NGNE
Sector
Market Cap
$237.2M
$45.8M
Price % of 52-Week High
21.44%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-44.77%
-32.38%
Beta (5-Year)
1.123
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$17.70
200-day SMA
Sell
Level
$35.76
Bollinger Bands (100)
Sell
Level
21.29 - 48.93
Chaikin Money Flow
Sell
Level
-4.4M
20-day SMA
Sell
Level
$20.71
Relative Strength Index (RSI14)
Sell
Level
28.38
ADX Line
Sell
Level
28.79
Williams %R
Buy
Level
-92.25
50-day SMA
Sell
Level
$25.78
MACD (12, 26)
Sell
Level
-2.60
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
109.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions.
Stock Forecast FAQ
In the current month, NGNE has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NGNE average analyst price target in the past 3 months is $52.80.
-
Where Will Neurogene Stock Be In 1 Year?
According to analysts, the consensus estimate is that Neurogene share price will rise to $52.80 per share over the next 12 months.
-
What Do Analysts Say About Neurogene?
Analysts are divided on their view about Neurogene share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Neurogene is a Sell and believe this share price will drop from its current level to $45.00.
-
What Is Neurogene's Price Target?
The price target for Neurogene over the next 1-year time period is forecast to be $52.80 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NGNE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Neurogene is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NGNE?
You can purchase shares of Neurogene via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Neurogene shares.
-
What Is The Neurogene Share Price Today?
Neurogene was last trading at $15.62 per share. This represents the most recent stock quote for Neurogene. Yesterday, Neurogene closed at $15.95 per share.
-
How To Buy Neurogene Stock Online?
In order to purchase Neurogene stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Morgan Stanley Stock Be in 10 Years?
Morgan Stanley (NYSE:MS) share price has been on a tear,…
Is Philip Morris Stock Overvalued?
If there is one industry that can be termed truly…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 123x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Alerts
Buy
58
WNS alert for Jan 23
WNS (Holdings) [WNS] is up 23.57% over the past day.
Sell
39
EA alert for Jan 23
Electronic Arts [EA] is down 16.73% over the past day.
Buy
52
HZO alert for Jan 23
MarineMax [HZO] is up 16.71% over the past day.
